EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015

  • ID: 3345050
  • Report
  • June 2015
  • Region: Global
  • 168 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • BIND Therapeutics, Inc.
  • Boston Biomedical, Inc.
  • Exelixis, Inc.
  • Johnson & Johnson
  • MORE
This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects.

the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • AstraZeneca Plc
  • BIND Therapeutics, Inc.
  • Boston Biomedical, Inc.
  • Exelixis, Inc.
  • Johnson & Johnson
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview
Therapeutics Development
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview
Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca Plc
ATLAB Pharma SAS
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Eli Lilly and Company
Exelixis, Inc.
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Pfizer Inc.
Sanofi
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AdIL-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-228 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBI-503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enfortumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mitomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vandetanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Product Development Milestones
Featured News & Press Releases
May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Amgen Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Astellas Pharma Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca Plc, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by ATLAB Pharma SAS, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by BIND Therapeutics, Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Eli Lilly and Company, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Exelixis, Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Incyte Corporation, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Johnson & Johnson, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Merck & Co., Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Pfizer Inc., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H1 2015
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H1 2015
Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca Plc
ATLAB Pharma SAS
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Eli Lilly and Company
Exelixis, Inc.
Incyte Corporation
Johnson & Johnson
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Pfizer Inc.
Sanofi
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll